Biogen (NASDAQ:BIIB) Price Target Raised to $244.00

Posted by Brian Himes on Oct 25th, 2026

Biogen (NASDAQ:BIIB – Free Report) had its price target increased by Bank of America from $219.00 to $244.00 in a research note released on Thursday morning, MarketBeat reports. Bank of America currently has a neutral rating on the biotechnology company’s stock.

A number of other research analysts have also recently commented on BIIB. Barclays increased their target price on shares of Biogen from $185.00 to $200.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 29th. Canaccord Genuity Group lifted their price target on shares of Biogen from $245.00 to $248.00 and gave the company a “buy” rating in a report on Thursday, July 30th. TD Cowen lifted their price target on shares of Biogen from $225.00 to $250.00 and gave the company a “buy” rating in a report on Wednesday. Stifel Nicolaus set a $242.00 price objective on shares of Biogen in a research report on Thursday, September 10th. Finally, Weiss Ratings raised shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, September 24th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $241.89.

Check Out Our Latest Report on Biogen

Biogen Price Performance

Shares of BIIB stock opened at $250.69 on Thursday. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. Biogen has a twelve month low of $138.00 and a twelve month high of $254.41. The company has a market cap of $37.04 billion, a P/E ratio of 44.37, a P/E/G ratio of 2.80 and a beta of 0.09. The business has a fifty day simple moving average of $223.60 and a 200 day simple moving average of $206.04.

Biogen (NASDAQ:BIIB – Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating the consensus estimate of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The business had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. During the same period last year, the firm posted $5.47 earnings per share. Biogen’s revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, sell-side analysts forecast that Biogen will post 12.29 EPS for the current fiscal year.

Institutional Trading of Biogen

A number of hedge funds have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in Biogen during the 2nd quarter worth approximately $3,453,878,000. Orbimed Advisors LLC bought a new position in shares of Biogen during the first quarter valued at $11,293,000. Tidal Investments LLC raised its stake in shares of Biogen by 9.0% during the second quarter. Tidal Investments LLC now owns 63,842 shares of the biotechnology company’s stock valued at $13,794,000 after acquiring an additional 5,256 shares during the last quarter. Saudi Central Bank raised its stake in shares of Biogen by 89.7% during the second quarter. Saudi Central Bank now owns 10,273 shares of the biotechnology company’s stock valued at $2,220,000 after acquiring an additional 4,858 shares during the last quarter. Finally, Nippon Life Global Investors Americas Inc. acquired a new position in shares of Biogen during the second quarter worth $29,648,000. 87.93% of the stock is owned by institutional investors and hedge funds.

About Biogen

(Get Free Report)

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.